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SUMMARY 
The purpose of our retrospective three-year-study was to analyse and compare clinical and 
epidemiological characteristics in hospitalized patients older than six years with community-
acquired pneumonia (CAP) caused by Chlamydia pneumoniae (87 patients) and Mycoplasma 
pneumoniae (147 patients). C. pneumoniae and M. pneumoniae infection was confirmed by 
serology. C. pneumoniae patients were older (42.12 year vs. 24.64 year), and were less likely 
to have a cough, rhinitis, and hoarseness (p<0.001). C. pneumoniae patients had higher levels 
of C-reactive protein (CRP), and aspartate aminotransferase (AST) than M. pneumoniae 
patients (p<0.001). Pleural effusion was recorded more frequently in patients with M. 
pneumoniae (8.84% vs.3.37%). There were no characteristic epidemiological and clinical 
findings that would distinguish CAP caused by M. pneumoniae from C. pneumoniae. 
However, some factors are indicative for C. pneumoniae such as older age, lack of cough, 
rhinitis, hoarseness,  and higher value of CRP, and AST.  
 
KEY WORDS: Community-acquired pneumonia, Chlamydia pneumoniae, Mycoplasma 
pneumoniae 
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INTRODUCTION 
Atypical pneumonia agents such as Chlamydia pneumoniae and Mycoplasma pneumoniae are an 
important cause of community-acquired pneumonia (CAP) [1]. The prevalence of CAP caused 
by C. pneumoniae and M. pneumoniae varies from 3-43% of all CAP cases [2-7]. These 
organisms share similar epidemiological and clinical characteristics in human infection and 
disease [8]. Pneumonia caused by these pathogens is usually associated with low severity but this 
may vary with the patient′s age, the presence of co-pathogens, or the existence of co-morbidity 
[9]. The diagnosis of C. pneumoniae and M. pneumoniae CAP has been made by several 
diagnostic techniques: antibody tests, culture, antigen detection, and identification of specific 
DNA sequences by polymerase chain reaction (PCR) [10]. The isolation and identification of C. 
pneumoniae and M. pneumoniae is difficult, time consuming, not routinely available and 
expensive [11]. Serology remains the main diagnostic tool in clinical practice. 
C. pneumoniae has been associated with atherosclerotic cardiovascular disease including 
coronary artery disease [12]. However, C. pneumoniae may cause acute exacerbation of chronic 
obstructive pulmonary disease (COPD) [13]. The microbiological eradication of C. pneumoniae 
may be difficult with effective antimicrobial therapy even when good clinical response occurs 
[14]. Failure to eradicate may have significant clinical consequences such as reactivation of 
COPD, most concerning in association with coronary artery disease [15, 16].  
M. pneumoniae is responsible for producing a wide spectrum of non-pulmonary 
manifestations including neurological, hepatic, cardiac, and hematological manifestations [17]. 
Central and peripheral nervous system manifestations are common complications associated with 
M. pneumoniae infection [18]. The outcome of CNS involvement ranges from normal to severe 
residual deficits [19]. 
We studied a group of 89 patients with CAP caused by C. pneumoniae and compared 
them with 147 patients with CAP caused by M. pneumoniae. Serological tests are regarded as 
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diagnostic, although the results are usually not available in a timely manner. The hypothesis is 
that clinical, radiological, and laboratory manifestations of the pneumonia caused by C. 
pneumoniae closely resemble those of M. pneumoniae. The goal of this study was to determine 
whether we may distinguish pneumonia caused by C. pneumoniae from M. pneumoniae on the 
basis of epidemiological, clinical, laboratory and radiological characteristics before serological 
confirmation of infection. The goal was also to establish a presumptive diagnosis of pneumonia 
that can be useful for both prognostic and therapeutic purposes.   
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METHODS 
We analyzed retrospectively patients with CAP caused by C. pneumoniae and M. pneumoniae 
hospitalized at the University Hospital for Infectious Diseases Zagreb, during the three year 
period from January 1, 1998 to December 31, 2000. The University Hospital for Infectious 
Diseases Zagreb serves a population of 1,000.000 inhabitants of Croatia’s capital, Zagreb, and its 
surrounding region. Annually, 600 to 800 patients of all ages are hospitalized with CAP, 
accounting for about 10% of all hospitalized patients.  
Patients who met the following criteria were included in the study: age older than six 
years, clinical findings suggestive of pneumonia (cough, fever, rales), evidence of a new 
pulmonary infiltrate on chest X-ray, and confirmed acute infection of C. pneumoniae and M. 
pneumoniae. Exclusion criteria included nosocomial pneumonia, patients with active 
tuberculosis, HIV positive patients, and patients who were discharged from hospital less than 21 
days prior to their current hospitalization due to pneumonia. 
The diagnosis of C. pneumoniae and M. pneumoniae infection was based on serological 
testing of antibodies. C. pneumoniae was diagnosed by microimmunofluorescence (MIF) based 
on C. pneumoniae elementary bodies (Savyon Diagnostics LTD, Israel) as antigen to detect 
specific IgG, IgA and IgM antibodies. Evidence of acute infection was defined as four-fold rise 
in C. pneumoniae antibody titre between acute and convalescent serum samples or an IgM 
antibody titre of ≥ 16. Patients with a serum IgG titre of ≥ 512 in both acute and convalescent 
serum samples without a four-fold rise in titre in convalescent serum were excluded.  
Serum antibodies to M. pneumoniae were assayed by enzyme-linked immunosorbent 
assay (ELISA) by using P1 membrane protein as antigen (Savyon Diagnostics LTD, Israel). 
Evidence of infection was defined as either a single positive serum IgM titre (≥ 10) in any serum 
sample or four-fold increase in IgG titre in paired sera.  
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Paired serum samples were tested for antibodies to Chlamydia psittaci, Legionella pneumophila 
and Coxiella burnetii. In addition, urine samples from patients were tested for L. pneumophila 
serogroup-1 antigen. Also we performed blood culture specimens and in selected patients sputum 
culture prior to antibiotic therapy. 
We analysed epidemiological data (age, gender, and cluster of patients, seasonal 
variations, date of onset of present illness, underlying comorbidity), clinical signs and symptoms 
(fever, cough, headache, chest pain, hoarseness, sore throat, rhinitis, myalgias/arthralgias, 
vomiting, diarrhoea), and laboratory findings (erythrocyte sedimentation rate, white blood cell 
count, sodium, aspartate aminotransferase, alanine aminotransferase, C-reactive protein, alpha-2 
globulin, urine, electrocardiogram).  
A chest radiograph was obtained on admission to hospital. The radiological 
manifestations of pulmonary infiltrates were described as: interstitial infiltrate, 
bronchopneumonia or alveolar infiltrate.  
Statistical analysis 
Means and standard deviations were calculated to summarize continuous variables. For 
categorical variables, group percentages were calculated. Differences between patient groups 
were calculated using the Fisher`s exact one-tailed test for categorical variables and Student`s t-
test for continuous variables. Results were considered significant at p value <0.05. All tests were 
performed with the STATISTICA for Windows software package [20]. 
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RESULTS 
From January 1 1998 to December 31 2000, we studied 89 patients with CAP caused by C. 
pneumoniae and 147 caused by M. pneumoniae treated at the University Hospital for Infectious 
Diseases Zagreb. These were chosen out of a larger group of 1,285 hospitalized patients with 
CAP older than six years including 774 (60.73%) patients whose serum samples were tested for 
evidence of infection. C. pneumoniae was confirmed in 89 patients, accounting for 6.93 % of all 
patients with CAP, and 11.5 % of patients whose serum samples were tested. Of these, 11 
patients had more than one pathogen identified as a cause of pneumonia. S. pneumoniae, as a 
copathogen, was confirmed in six, M. pneumoniae in three, and L. pneumophila in two patients. 
M. pneumoniae infection was confirmed in 147 patients, accounting for 11.44 % of all CAP 
patients, and 18.99 % of patients whose serum samples were tested. Ten patients with M. 
pneumoniae infection had a copathogen. S. pneumoniae was confirmed in five, C. pneumoniae in 
three, and L. pneumophila in one patient. 
The patients with C. pneumoniae infection and M. pneumoniae infection are presented 
in Table 1. The majority of patients were males in both study groups (p= 0.022). The mean 
age in the C. pneumoniae group was 42.12±17.92 years, significantly higher compared to the 
M. pneumoniae group (24.64±13.59 years; p<0.028). There were significant differences 
between C. pneumoniae patients and M. pneumoniae patients in terms of comorbidity (14/89 
vs. 9/147; p=0.016). Nearly one third of patients in both groups were smokers (p=0.426). The 
duration of symptoms prior to admission to hospital was similar (6.24 vs. 6.53 days; 
p=0.989). A lower incidence of C. pneumoniae than M. pneumoniae patients had a history of 
contact with a person with similar symptoms (12/89 vs. 45/147; p=0.002). Most cases of 
mycoplasma outbreaks occured in schools (22), among family members (13), and military 
recruits (10). Six patients with C. pneumoniae CAP but none with M. pneumoniae infection 
came from nursing homes. 
 8 
The oldest patient with C. pneumoniae CAP was 85 years of age (Table 2). CAP caused by C. 
pneumoniae was uncommon in school-age children, and its occurrence increased with age. 
Eighty patients (20.22%) were in the 20-29 age group, nine (10.11%) were aged 30-39, 21 
(23.60%) were aged 40-49, 14 (15.73%) were aged 50-59, and 17 (19.10%) were 60 years or 
older. Mycoplasma pneumoniae most frequently affected older children and younger adults (ages 
15 to 30 years). The oldest patient with M. pneumoniae CAP was 65 years old.  
The seasonal distribution of C. pneumoniae infections is showed in Table 3. A higher 
proportion of C. pneumoniae patients was recorded in summer months, between June and 
October while M. pneumoniae was more frequent between August and November.  
Patients in both groups had similar signs and symptoms on admission to hospital (Table 
4). The most common symptoms in patients with C. pneumoniae and M. pneumoniae infection 
were fever (97.75 vs. 97.96%), cough (82.02% vs. 97.28), and headache (53.06 vs. 59.55%), 
respectively. Patients with C. pneumoniae CAP were less likely to have a cough on admission 
(p<0.001). Upper respiratory tract symptoms were less commonly associated with C. 
pneumoniae CAP than with M. pneumoniae CAP. Gastrointestinal tract symptoms such as 
vomiting (p=0.029) and diarrhoea (p=0.056) were more commonly associated with C. 
pneumoniae. Patients in both groups had similar laboratory results (Table 5 and 6). The mean 
erythrocyte sedimentation rate (ESR) did not significantly differ between the Chlamydia and 
Mycoplasma group (p=0.900), but more patients in the Chlamydia group had accelerated ESR 
(p=0.047). The mean leucocyte count was similar in both groups of patients (10.32x109/L vs. 
9.87x109/L; p=0.310). Fifty one patients (57.3 %) from the C. pneumoniae group and 86 
(58.50%) from M. pneumoniae group had normal leucocyte count (p=0.481). The major 
difference among the groups regarding laboratory results was recorded in the C-reactive protein 
(CRP) and aspartate aminotransferase (AST) levels. Patients with C. pneumoniae CAP had 
higher levels of CRP (178.3±129.81 mg/L), and AST (33.93±31.91 IU/L) than M. pneumoniae 
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(100.9±87.73 mg/L; 22.58±17.63 IU/L, respectively). The differences were statistically 
significant (p<0.001; p<0.001, respectively). More than one third of C. pneumoniae patients and 
one-fifth of M. pneumoniae patients had increased level of AST and ALT (p=0.019; p=0.013, 
respectively). 
Radiological manifestations of pneumonia in the C. pneumoniae group were as follows: 
interstitial infiltrate in 79 (88.76 %), homogeneous segmental or lobar in five (5.62 %), and 
bronchopneumonia in five patients (5.62 %). Seven patients had multiple-lobe involvement (7.86 
%), and only three patients had pleural effusion (3.36%). Out of 147 patients with M. 
pneumoniae CAP chest X-ray showed interstitial infiltrate in 133 (90.48%), alveolar infiltrate in 
13 (8.84%), and bronchopneumonic infiltrate in one patient (0.68 %). Ten patients (6.80 %) had 
involvement more than one lobe, and pleural effusion had 13 patients (8.84 %). The two 
aetiological groups could not be differentiated by radiographic findings on admission.  
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DISCUSSION 
One thousand two hundred and eighty five patients with CAP who had been hospitalized at 
the University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb were included 
in a retrospective study conducted over a course of three years. They were residents of Zagreb 
or its surrounding area, including both genders and older than six years. C. pneumoniae and 
M. pneumoniae were common causes of pneumonia in our study (6.93% and 11.44%, 
respectively). The most prevalent concomitant aetiological agent was S. pneumoniae in both 
patient groups. The limitation of the study was its reliance on serological techniques alone for 
the diagnosis of C. pneumoniae and M. pneumoniae infection. The preferred diagnostic 
finding is documentation of a four-fold increase in titre from acute to convalescent specimen, 
with supporting evidence by PCR or culture [21, 22].  
M. pneumoniae was the most commonly confirmed pathogen of CAP described in our 
previously published report [23]. M. pneumoniae causes a small percentage of cases of CAP 
requiring hospitalization [24]. The incidence of infection with M. pneumoniae among 
hospitalized adults with CAP ranges from 3 to 30 % [4, 6, 25], and it is much higher among 
young adults who are treated as outpatients [26]. Although the prevalence varies from year to 
year and between different geographic settings, C. pneumoniae causes approximately 5-15% of 
cases of CAP [2-4, 27, 28]. The majority of cases of pneumonia are relatively mild and 
associated with low mortality.  
In the present study C. pneumoniae affected adults of all ages with the most frequent 
incidence in the 40-49 age group. M. pneumoniae infection was most common among older 
children and young adults. The mean age of patients with C. pneumoniae CAP was significantly 
higher than that of M. pneumoniae CAP. On the basis of serological criteria 11 (12.56%) patients 
with C. pneumoniae CAP had an acute primary infection (IgM antibody response), and 78 
(87.44%) patients had a recurrent acute infection. Only three of our patients were heavy smokers 
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with chronic obstructive pulmonary disease (COPD). C. pneumoniae may lead to inhibition of 
ciliary motion and facilitate infection of the lower respiratory tract [13]. Five of our patients with 
serologically confirmed C. pneumoniae infection had a heart disease. Of those five, two patients 
had severe pneumonia with S. pneumoniae as co-pathogen. The patients were discharged as 
improved, but after prolonged hospital stay. However, clinical characteristics in these patients 
may reflected manifestations of S. pneumoniae, with C. pneumoniae aggravating the cardiac 
disease. Certainly, C. pneumoniae infection has been associated with cardiovascular diseases 
[12]. Our study has shown that elderly patients, and those with underlying diseases had an 
elevated risk of CAP caused by C. pneumoniae, and co-morbidities undoubtedly played a 
significant role in the clinical course. 
Other studies described similar finding and reported that the highest incidence of C. pneumoniae 
pneumonia was among the elderly, and M. pneumoniae in adolescents and young adults [4, 7, 
25-27]. Males were affected more often than females in both groups of patients which 
corresponds to findings of other researches [4-7, 25-27]. 
In our study, a higher incidence of C. pneumoniae CAP was recorded between June and 
October, but M. pneumoniae infection had the highest incidence in the fall. We noted a small 
outbreak of C. pneumoniae infection during the summer months in 1999.  It was preceded by a 
great epidemic of M. pneumoniae pneumonia from August to December. Year 1999 was 
recorded as CAP epidemic caused by both C. pneumoniae, as well as M. pneumoniae. In the 
interepidemic period, we recorded no significant differences in the incidence of CAP in this two 
patient groups. Both CAP groups occurred throughout the observed period with somewhat lower 
incidence during the winter months.  
Several publications have recorded no seasonal differences in the incidence of C. 
pneumoniae CAP [29,30] although one study described C. pneumoniae infection during all 
seasons with higher incidence in summer months [31]. C. pneumoniae epidemics are 
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characterised by an initial high incidence period which lasts a few months to two-three years 
followed by three-four years of lower incidence [32].  Some studies suggest that there is no 
seasonal variation in M. pneumoniae infection; however, other data suggest that its incidence is 
greatest during the autumn and winter months [33]. For less clear reasons, M. pneumoniae 
outbreaks occur every 3-6 years [22, 33, 34]. 
Several differences between the symptoms produced by C. pneumoniae and M. 
pneumoniae were recorded. The patients with C. pneumoniae were less likely to have a cough 
and upper respiratory tract symptoms (rhinitis, hoarseness and sore throat) than patients with M. 
pneumoniae  CAP. Analysis of the laboratory findings in our study showed that CRP as well as 
AST were the most important laboratory findings in differentiating C. pneumoniae from M. 
pneumoniae CAP. The reason is that C. pneumoniae invades the blood and spreads into different 
organs, while M. pneumoniae remains on the respiratory tract epithelial causing a waeker 
inflammatory reaction with lower values of CRP and AST. The results suggest that CAP caused 
by C. pneumoniae is a more severe disease than pneumonia caused by M. pneumoniae. However, 
higher a proportion of C. pneumoniae patients had an increased aminotransferases level. There 
were no differences regarding radiological presentation of pneumonias, and most patients had 
intestitial infiltrates. Pleural effusion was more frequently recorded in M. pneumoniae patients. 
Numerous studies indicate that clinical symptoms, laboratory findings, and radiographic 
manifestations of C. pneumoniae pneumonia resemble those in patients with M. pneumoniae 
pneumonia [1, 8, 9, 25, 27]. Pneumonia caused by these pathogens is usually mild, but in some 
cases it can be severe even in normal healthy individuals [35, 36]. 
Electrocardiographic changes were found in nearly one-third of our patients. All ECG 
manifestations were transient and all patients completly recovered. Seedat et al. described ECG 
changes in 31% of patients of CAP [37]. Mechanisims of ECG changes in patients with 
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pneumonia may be multifactorial and may include hypoxia, electrolyte changes, adrenergic 
stimulation, and direct cardiac involvement [37].   
In conclusion, there are no clinical signs or symptoms or routine, rapid laboratory tests 
that would differentiate C. pneumoniae CAP from M. pneumoniae CAP. However, some features 
of C. pneumoniae infection are indicative, such as older age of patients, cough and symptoms 
from the upper respiratory tract (rhinitis, hoarseness), and higher values of CRP and AST.  
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Table 1. Baseline demographic and epidemiological details of patients with CAP caused by C. pneumoniae and 
M. pneumoniae 
 
 
Characteristics    C. pneumoniae               M. pneumoniae       P-value 
                      N = 89 ( %)      N = 147 
 
Males                      73 (82.02%)                    102 (69.39%)        0.022* 
 
Females        16 (17.98%)        45 (30.61%) 
 
Age (year)        42.12 ± 17.92                      24.64± 13.59        0.028** 
 
Comorbidity1       14 (15.73%)          9 (6.12%)        0.016* 
 
Current smoker               26 (29.21%)         46(31.29%)        0.426* 
 
Outbreak2        12 (13.48%)         45 (30.61%)        0.002* 
 
Duration of symptoms prior                   6.24±2.79           6.53±2.71        0.989** 
to admission 
CAP: community acquired pneumonia 
1Comorbidity: liver disease, renal disease, congestive heart failure, cerebrovascular disease, neoplastic disease, 
chronic obstructive pulmonary disease 
2Outbreaks in families, schools, military barracks, nursing homes 
Statistical analysis: * Fisher`s exact one-tailed test; ** Student`s t-test  
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Table 2. Age-specific rates of infection in patients with CAP caused by C. pneumoniae and M. pneumoniae 
 
________________________________________________________________________ 
                 Age group 
       (Year)               C. pneumoniae   M. pneumoniae 
           No                           %                      No           % 
___________________________________________________________________________________ 
7 – 14     3    3.37                 27  28.36 
15 – 19     7    7.87    34  23.13 
20 – 29    18  20.22    44  29.93 
30 – 39     9  10.11    23  15.64 
40 – 49    21  23.60     8   5.45 
50 – 59    14  15.73     8   5.45 
60 >    17  19.10     3   2.04 
Total    89             100.00  147                    100.00 
CAP: community acquired pneumonia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
 
Table 3. Distribution of infection in patients with CAP caused by C. pneumoniae and M. pneumoniae by months 
of the year 
 
 
Month         C. pneumoniae  M. pneumoniae 
  No.                 %          No         % 
___________________________________________________________________________________ 
January         4                  4.49  2        1.36      
February         5                  5.62  0           0 
March       3                  3.37  1        0.68 
April       4                  4.49  7        4.76 
May         4                  4.49  7        4.76 
June       16               17.98        2        1.36 
July       14               15.73      11        7.48 
August         6                  6.74      16      10.89 
September       10               11.24      26      17.69 
October         7                  7.87      34      23.13 
November         8                  8.99      34      23.13 
December         8                  8.99  7        4.76 
___________________________________________________________________________________ 
Total             89             100.00       147    100.00 
CAP: community acquired pneumonia 
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Table 4. Symptoms in patients with CAP caused by C. pneumoniae and M. pneumoniae  
   
 
  C. pneumoniae   M. pneumoniae    
Symptoms   _______________________________________________  p-value 
    No.  %             No    % 
___________________________________________________________________________________________________ 
 
Temperature (>37.5°C)   87  97.75             144  97.96   0.617 
Cough     73  82.02                 143  97.28              <0.001 
Rhinitis      6   6.74              45  30.61              <0.001 
Hoarseness    14               15.74              52  35.37              <0.001 
Sore throat     8    8.99              22  14.87   0.127 
Chest pain     8    8.99              22  14.87   0.127 
Headache     53  59.55              78  53.06   0.201 
Vomiting    17  19.10              14    9.52   0.029 
Diarrhoea    10  11.24                7    4.70   0.056 
Myalgias/arthralgias   36  40.45              48  32.65                0.142 
Pleural effusion     3    3.33              13    8.84   0.101 
__________________________________________________________________________________________________ 
CAP: community acquired pneumonia 
Statistical analysis:  Fisher`s exact one-tailed test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
Table 5. Normal range and pathological laboratory findings in patients with CAP caused by C. pneumoniae 
and M. pneumoniae 
 
 
                     Pathological finding  
Laboratory finding Normal range  C. pneumoniae M. pneumoniae         P-value 
                      N = 89   N = 147 
_________________________________________________________________________________ 
 
ESR ↑   >20 mm/1.h        81      121       0.047  
   
CRP ↑   10 mg/L                   50/50       86/95       0.392  
 
WBC ↑   4-10x109/L       38      61       0.481  
            
AST ↑   11-38 IU/L        34     36       0.019  
     
ALT ↑   12-48 IU/L                 30     29       0.013  
          
Alpha-2 globulin ↑ 5.5-9.5 rel.%       62     91        0.142  
    
Gamma globulin ↑ 14.5-19.5 rel%       29     36       0.116  
               
Sodium ↓               138-146 mmol/L       50     74       0.231  
   
Abnormal ECG                   32/76               42/125       0.248     
___________________________________________________________________________________ 
Statistical analysis: Fisher`s exact one-tailed test  
CAP: community acquired pneumonia 
↑ - increased values 
↓ - decreased values 
ESR = Erythrocyte sedimentation rate 
CRP = C-reactive protein 
WBC = White blood cell 
AST = Aspartate aminotransferase 
ALT = Alanine aminotransferase 
ECG = Electrocardiogram 
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Table 6. Laboratory findings in patients with CAP caused by C. pneumoniae and M. pneumoniae  
 
 
    C. pneumoniae    M. pneumoniae   
Laboratory finding  ________________________________________      p-value 
    X±SD        Range    X±SD           Range 
___________________________________________________________________________________ 
 
ESR (mmHg/1.h)                    58.82±24.46           8-130         47.64±24.79          6-112               0.900 
 
CRP mg/L (N=95; N=50)      178.3±129.81        12-496          100.9±87.73        2-331        <0.001 
 
WBC (x109/L)                     10.32±4.30         4.6-29.0           9.87±3.91       3.8-35.8             0.310 
 
AST (IU/L)          33.93±31.91           8-137           22.58±17.63       8-137              <0.001 
 
ALT (IU/L)          41.22±43.77          11-212           27.52±37.13       7-383               0.079 
 
Alpha-2 (rel.%)        11.26±2.43       6.9-17.1          10.14±2.20        5.4-16.5              0.271 
 
Gamma (rel.%)        16.64±3.06      11.2-28.6         16.51±2.80          9.4-25.9             0.336 
 
Sodium (mmol/L)                136.87±2.67       128-142         137.41±2.67       130-144               1.000 
___________________________________________________________________________________ 
CAP: community acquired pneumonia 
Statistical analysis: Student`s t-test  
ESR = Erythrocyte sedimentation rate 
CRP = C-reactive protein 
WBC = White blood cell 
AST = Aspartate aminotransferase 
ALT = Alanine aminotransferase 
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Abbreviations 
Alanine aminotransferase – ALT 
Aspartate aminotransferase – AST 
Chlamydia pneumoniae – C. pneumoniae 
Chlamydia psittaci – C. psittaci  
Community-acquired pneumonia – CAP 
Coxiella burnetii – C. burnetii 
C – reactive protein – CRP 
Electrocardiogram – ECG 
Erythrocyte sedimentation rate – ESR 
International unit - IU 
Mycoplasma pneumoniae – M. pneumoniae 
Microimmunofluorescence –MIF 
Legionella pneumophila – L. pneumophila  
Polymerase chain reaction – PCR  
Streptoccocus pneumoniae – S. pneumoniae 
White blood cell – WBC  
 
 
 
 
 
 
